Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avidity Biosciences, Inc.RNA · Entity 11854 | Chief Medical Officer | February 02, 2021 | February 04, 2021 |
| Design Therapeutics, Inc.DSGN · Entity 4991 | Chief Medical Officer | March 13, 2024 | March 20, 2024 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Medical Officer | February 06, 2026 | February 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avidity Biosciences, Inc.
Report date February 02, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 82,000 |
Reported balance
After 2021-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-02 · Grant · Acquired 82,000 · Balance 82,000 F1: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 1, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 1, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.
Design Therapeutics, Inc.
Report date March 13, 2024 · Filed March 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,756 |
Reported balance
Holding disclosure · report date 2024-03-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,756 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.77 · Expires 2032-01-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-13 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The shares subject to the option will vest as follows: 25% of the shares vested on January 24, 2023, and the balance will vest in equal monthly installments thereafter over a three year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.97 · Expires 2033-01-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-13 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The shares subject to the option will vest as follows: 20% of the shares vested on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2034-01-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-13 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as follows: 25% of the shares vested on January 24, 2023, and the balance will vest in equal monthly installments thereafter over a three year period.
F2: The shares subject to the option will vest as follows: 20% of the shares vested on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.
F3: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.
Septerna, Inc.
Report date February 06, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2036-02-05 | Direct | 125,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000 F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 11, 2026 00:08 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001193125-26-045106 · ownership.xml · derivative · entry 1 Kim Jae B. · CIK 0001819159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-05 F1 · derivative.exercise_date: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 23:08 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0000950170-25-106796 · ownership.xml · derivative · entry 1 Kim Jae B. · CIK 0001819159 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-08-06 F1 · derivative.exercise_date: 2/48th of the shares subject to such option shall vest and become exercisable on October 1, 2025 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 21:49 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 82,000 | $0.00 Strike: $22.34 | $0.00 |
DisclosureSEC source: 0001209191-21-007765 · doc4.xml · derivative · entry 1 Kim Jae B. · CIK 0001819159 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 1, 2021 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2020 Filed Jul 27, 2020 21:03 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 375,266 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001209191-20-043749 · doc4.xml · derivative · entry 1 Kim Jae B. · CIK 0001819159 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,266 Underlying: Common Stock · 375,266 shares Expires 2030-07-26 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on July 27, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continuous service to the Registrant on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.